The Effect of Lymphocyte Therapy on the Expression of MicroRNAs in Women with Recurrent Pregnancy Loss

Recurrent Pregnancy Loss (RPL) is 2 or more recurrent miscarriages before the twentieth week, which occurs in 2-5% of women of gestational age. Considering the significant role of the immune system in the process of a successful pregnancy, it is expected that in addition to the common and well-known treatments used for patients with recurrent miscarriage to date, intracutaneous lymphocyte therapy will also be effective.

30 patients with RPL with immunological disorders, and 30 patients in a control group consisting of healthy women with a history of successful pregnancies were included in the study. After receiving blood samples and initial examinations, people with RPL received lymphocytic treatment. Before and after the intervention, the expression levels of miR-146a, miR-10a, miR-106b, and miR-25 were measured in both groups and the differences caused by the effects of this intervention were examined.

The expression of anti-inflammatory miR-146a and miR-10a, in women with RPL showed a significant increase after receiving lymphocyte treatment compared to before treatment. While the expression of pro-inflammatory miR-106b and miR-25 showed a significant decrease after receiving lymphocytes compared to before treatment.

The aim of intradermal lymphocyte therapy is to increase the maternal immune system's tolerance to paternal antigens in the fetus and to modulate inflammatory responses in pregnant women with RPL. According to the results of this study, this method can be used to reduce inflammation in women with recurrent miscarriage.